三氧化二砷治疗中晚期原发性肝癌的临床研究  

Clinical study of arsenic trioxide in the treatment of advanced primary liver cancer

作　　者：付静 时淑珍 

机构地区：[1]大连市肿瘤医院,大连116031

出　　处：《中国肿瘤临床与康复》2006年第3期232-233,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的研究三氧化二砷对中晚期原发性肝癌的疗效。方法治疗中晚期原发性肝癌共25例,单药三氧化二砷注射液10 mg,静脉滴注,1次/d,连用10 d为一周期,间歇2周重复。结果PR 4例,NC 17例,PD 4例,缓解率为16.0%。主要的不良反应为消化道反应、骨髓抑制及肝功能改变。结论三氧化二砷治疗原发性肝癌有效,且不良反应少,值得临床推广。Objective To study the efficacy of arsenic trioxide （Aa203 ） in treating primary liver cancer. Methods Twenty-five patients with advanced primary liver cancer were treated with As2O3 injection only at a dose of 10 mg/day by intravenous instillation for succesive 10 days and the treatment was repeated after 2 weeks. Results The response rate was 16.0% with 4 cases PR, 17cases NC and 4 cases PD. The major adverse reactions were mild G-I reaction, mild bone marrow suppression and hepatic fuctional damage. Conclusion As2O3 injection is effective in treating primary liver cancer and the adverse reactions are mild, so it is worthy of popularization.

关 键 词：肝肿瘤/药物疗法 三氧化砷 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]